Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor Journal Article


Authors: Johns, T. G.; Adams, T. E.; Cochran, J. R.; Hall, N. E.; Hoyne, P. A.; Olsen, M. J.; Kim, Y. S.; Rothacker, J.; Nice, E. C.; Walker, F.; Ritter, G.; Jungbluth, A. A.; Old, L. J.; Ward, C. W.; Burgess, A. W.; Wittrup, K. D.; Scott, A. M.
Article Title: Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
Abstract: The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial cancers, an observation often correlated with poor clinical outcome. Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. Monoclonal antibody (mAb) 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild type (wt) EGFR when overexpressed but does not bind the wt EGFR expressed in normal tissues. Despite only binding to a low proportion of the wt EGFR expressed in A431 tumor cells (∼10%), mAb 806 displays robust antitumor activity against A431 xenografts grown in nude mice. To elucidate the mechanism leading to its unique specificity and mode of antitumor activity, we have determined the EGFR binding epitope of mAb 806. Analysis of mAb 806 binding to EGFR fragments expressed either on the surface of yeast or in an immunoblot format identified a disulfide-bonded loop (amino acids 287-302) that contains the mAb 806 epitope. Indeed, mAb 806 binds with apparent high affinity (∼30 nM) to a synthetic EGFR peptide corresponding to these amino acids. Analysis of EGFR structures indicates that the epitope is fully exposed only in the transitional form of the receptor that occurs because EGFR changes from the inactive tethered conformation to a ligand-bound active form. It would seem that mAb 806 binds this small proportion of transient receptors, preventing their activation, which in turn generates a strong antitumor effect. Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity.
Keywords: signal transduction; controlled study; unclassified drug; human cell; gene deletion; antineoplastic agents; flow cytometry; protein conformation; gene overexpression; genes; gene amplification; epidermal growth factor receptor; cell line; protein binding; receptor, epidermal growth factor; antineoplastic activity; tumor xenograft; dose-response relationship, drug; cell line, tumor; transfection; time factors; mus musculus; genetic vectors; monoclonal antibodies; monoclonal antibody; blotting, western; immunology; antibodies, monoclonal; amino acid sequence; molecular sequence data; nude mouse; tumors; cell membrane; peptides; immunoblotting; ligands; plasmids; antibody specificity; models, molecular; protein structure, tertiary; enzyme-linked immunosorbent assay; surface plasmon resonance; receptor binding; epitopes; cells; monoclonal antibody 806; grafts; variation (genetics); humans; human; priority journal; article; epidermal growth factor receptors (egfr)
Journal Title: Journal of Biological Chemistry
Volume: 279
Issue: 29
ISSN: 0021-9258
Publisher: American Society for Biochemistry and Molecular Biology  
Date Published: 2004-07-16
Start Page: 30375
End Page: 30384
Language: English
DOI: 10.1074/jbc.M401218200
PROVIDER: scopus
PUBMED: 15075331
DOI/URL:
Notes: J. Biol. Chem. -- Cited By (since 1996):77 -- Export Date: 16 June 2014 -- CODEN: JBCHA -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Achim Jungbluth
    455 Jungbluth
  2. Gerd Ritter
    166 Ritter
  3. Lloyd J Old
    593 Old